A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST)

Trial Profile

A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST)

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Biomarker; Registrational; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results comparing nocebo effects in older patients (n=446) enrolled in cancer therapeutic trials (NCCTG97-24-51 and ACOSOG Z9001), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 19 Jun 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.(Parent trial: NCT00041197).
    • 19 Jun 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.(Parent trial: NCT00041197).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top